Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs NetApp Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.67 (market cap $8.04B), while NetApp Inc. trades at $166.51 (market cap $34.20B). The key difference: NetApp Inc. is far larger — about 4.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and NetApp Inc. pays a 1.19% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NTAP | |
|---|---|---|
Market Cap | $8.04B | $34.20B |
Sector | Health | Technology |
52-Week High | $339.75 | $181.08 |
52-Week Low | $241.71 | $94.11 |
Enterprise Value | $7.85B | $33.35B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NetApp (NTAP) trades at $163.93, down 2.93% on the day, but maintains a bullish technical stance with strong moving averages and support near $162. The company demonstrates robust fundamentals with a 70.74% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.43 versus $2.27 expected. Recent news highlights AI-driven growth opportunities, such as StorageGRID 12.1 enhancements for AI workloads announced on June 23, 2026.
Outlook remains positive with analyst consensus target at $167.45, offering modest upside. Key opportunities include enterprise AI demand and all-flash storage adoption, while risks involve competitive pressures and debt levels rising to 29.89% of assets. The stock's valuation at a P/E of 25.82 warrants monitoring amid sector comparisons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
